The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Official Title: A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Study ID: NCT01217229
Brief Summary: PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.The primary objective of this study is to evaluate the efficacy, as measured by overall response rate, of orally administered PLX3397 in patients with relapsed or refractory classical Hodgkin lymphoma (HL). Secondary objectives include safety, the duration of response, the disease control rate, progression free survival, and how the drug affects your body.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Northwestern University, The Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
Mayo Clinic, Rochester, Minnesota, United States
Nebraska Medical Center, Omaha, Nebraska, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
MD Anderson Cancer Center, Houston, Texas, United States